- Dianosic has been selected by “Startup” and featured in the “101 Best France Medical Device Startups” article.
- Learn more 👉🏼 https://startupill.com/101-best-france-medical-device-startups/
Intranasal bleeding (epistaxis) affects about 10% of the population, i.e. 750 million people worldwide. Patient management requires to understand precisely the underlying cause(s) of bleeding.
Commonly referred to as “nosebleeds,” epistaxis results in nasal hemorrhage occurring in the mucous membranes lining the nasal cavity. The pathology of epistaxis is most often not serious. However, recurrent and persistent bleeding can hide a more serious condition.
There are two types of epistaxis:
Epistaxis is often caused by damage to the vascular network, and in particular the kiesselbach plexus, located in the anterior part of the nasal cavity.
Photo Credit: Laboratoires Brothier
There are several factors that can cause epistaxis to occur. Most often, these bleeds can be impressive but are not dangerous for patients.
The nasal mucosa is very fragile, lining the cavities of the nose irrigated by a highly developed network of blood vessels. Damage to those vessels can cause inflammation and then epistaxis.
This inflammation can occur in children as well as in adults, but also in people suffering from allergic rhinitis or even a simple cold. The latter can indeed lead to congestion of blood vessels in the nasal cavity and cause bleeding.
Located in the anterior part of the nasal cavity, the Kiesselbach complex can bleed very easily following nose-picking. Children are the most affected.
Other factors can increase the sensitivity of the blood vessels or capillaries in the nasal cavity and explain this bleeding:
These different factors can take on a greater magnitude in fragile populations such as children or elderlies.
Certain traumas of accidental or iatrogenic origin can trigger epistaxis:
Certain environmental factors can increase the risk of epistaxis, such as cold weather, change in altitude or dry air. Having very heated rooms in the winter or a dry climate will promote bleeding.
In rarer cases, epistaxis is a serious condition that may be triggered by a genetic disease, such as Rendu-Osler disease, or an anatomic condition such as a deviated septum.
Cardiovascular diseases may require the use of anticoagulants or antiaggregants, which can lead to coagulation disorders and thus promote the development of epistaxis.
High blood pressure, common in the elderly, can also cause intranasal bleeding.
Nosebleeds can also occur as a result of a disease such as:
In addition, both malignant (cancerous) and benign (non-cancerous) tumors of the nasal cavity often have the same symptoms, including frequent intranasal bleeding.
Regular alcohol consumption or repeated nasal drug use can potentially generate epistaxis.
In summary, there are many factors that can cause epistaxis to occur. This is why it is important to quickly identify the cause of the bleeding. In the majority of cases (nearly 90%), this bleeding is not dangerous and can be controlled by simple digital compression. On the other hand, if digital compression do not work and/or if they are frequent and abundant, specific treatment will be necessary.
Many treatments, most of them old, exist to treat epistaxis. At Dianosic, we have developed a non-invasive, easy to use and painless asymmetric balloon for the patient. If you want to learn more about this “Made in France” innovation, click on the following link 👉🏼 https://bit.ly/3qyHele
Dianosic, a Strasbourg-based startup specializing in innovative solutions for ear, nose, and throat (ENT) conditions, today announces that it has obtained CE marking for CAVI-TTM, a low-pressure asymmetric balloon for treating spontaneous and post-operative intranasal bleeding. This class IIa certification, obtained at the end of February, will enable the company to begin marketing the device in Europe.
CAVI-T, which is designed to treat intranasal bleeding (epistaxis), is patented in France and will be soon in Europe, the United States, Japan and China. It is the first asymmetric intranasal balloon that stops bleeding by applying low-force compression while adapting to the anatomy of the nasal fossa. The balloon can remain in place for one to three days.
At present, this atraumatic, easy-to-use medical device is aimed primarily at hospitals. A pilot study between April and June 2019, led by Professor Christian Debry, Head of the ENT department at Strasbourg University Hospital, demonstrated its safety and efficacy. The balloon was effective in stopping bleeding in 90% of patients and significantly improved their quality of life. This feasibility study also demonstrated the good safety profile of CAVI-T, with a mean pain score on product insertion and removal of 4.7 and 1.6 respectively. (Evaluated on a Visual Analogue Scale ranging from 1 to 10).
“Obtaining CE marking is an important recognition of Dianosic’s expertise and the ability of its team to conceive and develop innovative products to treat ENT disorders,” said Marc Augustin, President of Dianosic.
“Following this major step in our development, we are ready to prepare the commercial launch of the product in Europe, which is expected to take place during the second quarter of 2020. Dianosic’s entry into the market represents a prime opportunity for growth, with the potential to reach close to five million patients across Europe and the United States,” said Philippe Bastide, CEO of Dianosic.
Dianosic develops innovative solutions for the management of ENT conditions.
Incubated by SEMIA, named ‘incubator of excellence’ for the Grand Est region in January 2018, Dianosic is led by company President Marc Augustin and CEO Philippe Bastide. Professor Christian Debry, Head of the ENT department at Strasbourg University Hospital Center, acts as a scientific advisor to the company.
Dianosic was a winner at i-Lab 2019, an innovation contest run by Bpifrance and the Ministry of Higher Education, Research and Innovation. Dianosic was also selected to take part in a Soft-Landing program in Boston, MA in September 2019. This program was organized by Strasbourg Eurométropole and Innouvo in partnership with Cajuba Finance.
Founded in July 2017 and based in Strasbourg, Dianosic aims to become a European leader in the management of intranasal bleeding and chronic sinusitis with its active, long-term resorbable treatment
Dianosic is committed to the development of disruptive technologies in the field of Ear Nose and Throat (#ENT) and focuses more specifically on the nasal cavity. As we pursue our efforts to bring our disruptive solution to life in the field of #chronicsinusitis, we are glad to announce that Victor Moreau is joining the team as R&D Engineer.
Victor brings a solid knowledge in the formulation of resorbable polymers for biomedical applications. Victor also worked as a Quality Assistant at DEDIENNE SANTE. Those competencies will greatly contribute to the progress of our project. Victor, along with Sarah Zahouani (CTO, Dianosic) will work closely with the Polymers for Health and Biomaterials team, which has a renowned expertise in bioresorbable polymers. We’d like to thank Xavier Garric (Head of the, PHBM), the CNRS – Centre national de la recherche scientifique, the Université de Montpellier and the ENSCM for making this fantastic partnership, in which Victor will have a central position, a reality.
We look forward to having this team transform the way patients with chronic sinusitis will be treated in the future and pave the way for Dianosic upcoming successes.
Victor, a warm welcome to you!
As dianosic continues to make headway towards commercialization of its CAVI-T solution in intranasal bleeding, we are excited to inform you that Jacques PENICAUD will support us in preparing the launch of this innovative product.
During his career, Jacques held different positions at Johnson & Johnson ranging from Financial controller to Sales Director and Business Unit Director for the Medical Devices segment (Advanced Wound Care, Ethicon Biosurgery, Mitek and Advanced Sterilization Products). Jacques then pursued an external opportunity as the CEO of STERIENCE (sterilization business) before joining Abbott Vascular as General Manager.
Jacques will leverage his huge experience in the successful launch of disruptive medical technologies to strategize commercialization efforts for our CAVI-T solution.
Jacques, we look forward to disrupting the market together!! ????
#epistaxis #nosebleeds #ENT
We are thrilled to announce you that Isabelle Perez will support dianosic in its venture and help us prepare the upcoming commercialization of our CAVI-T device in intranasal bleeding.
During her tenure at Johnson & Johnson and LivaNova, Isabelle developed state of the art Professional Education strategies and tools. By ensuring proper training of healthcare professionals and promoting the optimal use of our technology, Isabelle will be a great contributor to our upcoming successes.
Welcome aboard Isabelle ???
In Morocco, in the footsteps of St Exupery, Courrier Sud is a 5 days running and mountain bike team (4 members) experience. Every other day, a team must have on the start lane 2 runners and 2 mountain-bikers for combined events (relays, race against time, pair race, race by four, individual race,….).
More than just a race, Courrier Sud is first and foremost and human adventure.
It is in that setting that Dianosic supported Eric Fesson, from Execution Consulting, and his teammates. Looking after a common goal, Eric and his team have demonstrated their ability to excel themselves with a flawless team spirit, getting all roadblocks out of their way. Dianosic is humbled to be associated with it and proud to have brought our small contribution to this beautiful venture. AWSOME! ???
More info at: